AgomAb Therapeutics NV
AGMB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002020932
No open-market purchases or sales by AgomAb Therapeutics NV insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $337.0M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding AgomAb Therapeutics NV changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 32 | 34 | +2 |
| Shares | 23.4M | 26.0M | +2.60M (+11.1%) |
| Value | $245.3M | $337.0M | +$91.7M (+37.4%) |
New holders (9)
Institutions that held AgomAb Therapeutics NV at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| OrbiMed Advisors LLC | 192,740 | $2.50M | 0.05% |
| Alps Advisors Inc | 49,984 | $648.8K | 0.00% |
| Quadrature Capital Ltd | 20,461 | $265.6K | 0.00% |
| XTX Topco Ltd | 10,271 | $133.3K | 0.00% |
| Citigroup Inc | 9,496 | $123.3K | 0.00% |
| GAMMA Investing LLC | 1,344 | $17.4K | 0.00% |
| BNP Paribas Arbitrage, SA | 754 | $9.79K | 0.00% |
| Larson Financial Group LLC | 698 | $9.06K | 0.00% |
| Caitong International Asset Management Co., Ltd | 2 | $26 | 0.00% |
Sold out (7)
Institutions that held AgomAb Therapeutics NV at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| LMR Partners LLP | 300,000 | $3.15M |
| Millennium Management LLC | 95,233 | $999.0K |
| Alyeska Investment Group, L.P. | 75,000 | $786.8K |
| Laurion Capital Management LP | 50,000 | $524.5K |
| Citadel Advisors LLC | 35,000 | $367.1K |
| D. E. Shaw & Co., Inc. | 15,326 | $160.8K |
| Jane Street Group, LLC | 12,794 | $134.2K |